2014 Press Releases

»2014 Press Releases
22 12, 2014

Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for HDV Infection

2017-02-07T19:05:33+00:00

Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for Hepatitis Delta Virus (HDV) Infection Palo Alto, Calif., December 22, 2014 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that lonafarnib has been granted Orphan Designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). The [...]

Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for HDV Infection2017-02-07T19:05:33+00:00
22 12, 2014

Eiger Bio Announces Positive Data in Patients Infected with HDV Treated with Lonafarnib – Results Presented at AASLD 2014 Meeting

2017-02-07T19:07:23+00:00

Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib – Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting Palo Alto, Calif., December 22, 2014 /PRNewswire/ -- Eiger BioPharmaceuticals Incorporated announced the positive results of a Phase 2a study of lonafarnib in [...]

Eiger Bio Announces Positive Data in Patients Infected with HDV Treated with Lonafarnib – Results Presented at AASLD 2014 Meeting2017-02-07T19:07:23+00:00